BioMarin CEO and leadership

Jean-Jacques Bienaime is a Board Member at Biotechnology Innovation Organization - BIO, Director at INCYTE CORP, and Chairman/CEO at BioMarin Pharmaceutical Inc and is based in Novato, California. He has experience at Rhône Poulenc Rorer and has worked as President/CEO at GENENCOR INTERNATIONAL INC, Board Member at NeurogesX Inc, and Marketing Director at Genentech. Jean attended ESCP Europe, Ecole Superieure de Commerce de Paris between 1974 and 1976, and University of Pennsylvania.

Jeff Ajer joined BioMarin in August 2005 and currently serves as the Executive Vice President and Chief Commercial Officer. From October 2012 to January 2014, Mr. Ajer served as the Senior Vice President and Chief Commercial Officer. From April 2009 to October 2012, Mr. Ajer served as the Vice President, Commercial Operations, The Americas, where he had responsibility for commercial operations throughout the Americas and led product marketing, reimbursement, and sales operations for BioMarin. Prior to joining BioMarin, Mr. Ajer served in various roles at Genzyme Corporation (Genzyme) beginning in November 2003, most recently as Vice President, Global Transplant Operations from December 2004 to August 2005. Mr. Ajer’s experience prior to Genzyme includes roles in sales, marketing and operations at SangStat Medical Corporation and ICN Pharmaceuticals. Mr. Ajer received both a B.S. in chemistry and an M.B.A. from the University of California, Irvine. Mr. Ajer is currently a director of Nektar Therapeutics, a public biopharmaceutical company.

C. Greg Guyer, Ph.D, joined BioMarin in May 2020 and currently serves as Chief Technical Officer and Executive Vice President of Global Manufacturing and Technical Operations, responsible for overseeing our manufacturing, process development, quality, supply chain, engineering and analytical chemistry departments. From 2015 to 2019, Dr. Guyer served in a number of increasingly responsible positions at Bristol Myers Squibb (BMS), primarily leading all of operations and biologic development. Prior to BMS, Dr. Guyer worked for Merck & Co., Inc., from 1994 to 2015, leading various global organizations in biologic and pharmaceutical operations, quality, regulatory, emerging markets strategy and enterprise systems. He currently serves on the Board of Directors for the University of Georgia Research Foundation.

Dr. Guyer earned his Ph.D. in analytical chemistry from American University, Bachelor of Science degree in chemistry from the University of Georgia and Master of Business Administration degree from Lehigh University.

Philip Lo Scalzo joined BioMarin Pharmaceutical Inc. in 2007 and currently serves as its Senior Vice President, Global Compliance & Ethics and its Chief Compliance Officer. In his role, Mr. Lo Scalzo is responsible for creating and maintaining the company’s global compliance program which includes Healthcare Compliance, GxP Compliance, Internal Audit, and Global Security. His responsibilities include overseeing the development and implementation of compliance policies, as well as employee and partner training; managing GxP audits of both company facilities and vendors; scoping and executing financial and operational internal audits, including audits of third-party vendors; coordinating enterprise risk assessments and analysis; review and approval of promotional materials; monitoring of promotional events and other interactions with healthcare professionals; management of investigations; implementation of corrective actions; and oversight of the global security program, which focuses on physical and personnel security.

Prior to this role, Mr. Lo Scalzo served as BioMarin’s Deputy General Counsel where he worked on a variety of legal and corporate compliance related matters. Before joining BioMarin, Mr. Lo Scalzo spent four years at Sanofi-Aventis where he served as an Assistant General Counsel supporting the organization’s cardiovascular commercial team, corporate compliance department, litigation, and human resources groups. Prior to joining Sanofi-Aventis, Mr. Lo Scalzo was an associate attorney in the New York office of Sedgwick, Detert, Moran & Arnold where his practice primarily focused on defending pharmaceutical product liability cases. Mr. Lo Scalzo received a J.D. from Brooklyn Law School and a B.A. from Boston College.

Jean-Jacques Bienaime is a Board Member at Biotechnology Innovation Organization - BIO, Director at INCYTE CORP, and Chairman/CEO at BioMarin Pharmaceutical Inc and is based in Novato, California. He has experience at Rhône Poulenc Rorer and has worked as President/CEO at GENENCOR INTERNATIONAL INC, Board Member at NeurogesX Inc, and Marketing Director at Genentech. Jean attended ESCP Europe, Ecole Superieure de Commerce de Paris between 1974 and 1976, and University of Pennsylvania.